AMLX Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. (AMLX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 15% planned / 85% discretionary
Largest single sale: $950.0K.
Where they traded
Last open-market purchase: May 21, 2026 , by Firestone Karen .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Cohen Joshua B 2 fills | Co-Chief Executive Officer | Sell | 30,464 | $32.19 | $980.5K | 3,614,042 −0.8% of holding | |
| Klee Justin B. 2 fills | Co-Chief Executive Officer | Sell | 30,464 | $32.18 | $980.3K | 3,614,495 −0.8% of holding | |
| FRATES JAMES M 2 fills | Chief Financial Officer | Sell | 10,810 | $32.36 | $349.8K | 234,667 −4.4% of holding | |
| Bedrosian Camille L 2 fills | Chief Medical Officer | Sell | 10,028 | $32.40 | $324.9K | 280,145 −3.5% of holding | |
| Mazzariello Gina 2 fills | Chief Legal Officer | Sell | 9,536 | $32.46 | $309.5K | 190,849 −4.8% of holding | |
| Mazzariello Gina | Chief Legal Officer | Sell 10b5-1 | 15,000 | $17.61 | $264.1K | 179,090 −7.7% of holding | |
| Mazzariello Gina | Chief Legal Officer | Sell 10b5-1 | 15,000 | $18.32 | $274.7K | 194,090 −7.2% of holding | |
| Firestone Karen | Director | Buy | 3,800 | $13.51 | $51.3K | 66,900 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.